Safety precaution: Nexavar (sorafenib)
July 2025
Nexavar (sorafenib): Risk of tumour lysis syndrome
Cases of TLS, some fatal, have been reported in post-marketing surveillance in patients treated with sorafenib.
Risk factors for TLS include high tumour burden, pre-existing chronic renal insufficiency, oliguria, dehydration, hypotension, and acidic urine.
These patients should be monitored closely and treated promptly as clinically indicated; prophylactic measures should be considered if clinically indicated.
More information: